nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCG2—Leflunomide—systemic scleroderma	0.143	0.197	CbGbCtD
Vemurafenib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0885	0.122	CbGbCtD
Vemurafenib—ALB—Captopril—systemic scleroderma	0.0775	0.107	CbGbCtD
Vemurafenib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0619	0.0853	CbGbCtD
Vemurafenib—ALB—Mycophenolate mofetil—systemic scleroderma	0.061	0.0841	CbGbCtD
Vemurafenib—CYP1A2—Leflunomide—systemic scleroderma	0.0591	0.0814	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—systemic scleroderma	0.0531	0.0731	CbGbCtD
Vemurafenib—ALB—Prednisone—systemic scleroderma	0.0488	0.0672	CbGbCtD
Vemurafenib—CYP2D6—Captopril—systemic scleroderma	0.0382	0.0526	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—systemic scleroderma	0.0355	0.0489	CbGbCtD
Vemurafenib—ALB—Methotrexate—systemic scleroderma	0.0245	0.0337	CbGbCtD
Vemurafenib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0191	0.0264	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—systemic scleroderma	0.0153	0.0211	CbGbCtD
Vemurafenib—BRAF—Signaling events mediated by focal adhesion kinase—GIT2—systemic scleroderma	0.0032	0.0577	CbGpPWpGaD
Vemurafenib—RAF1—Signaling events mediated by focal adhesion kinase—GIT2—systemic scleroderma	0.00222	0.0399	CbGpPWpGaD
Vemurafenib—BRAF—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00216	0.0389	CbGpPWpGaD
Vemurafenib—RAF1—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00149	0.0269	CbGpPWpGaD
Vemurafenib—RAF1—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.00103	0.0185	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.000933	0.0168	CbGpPWpGaD
Vemurafenib—BRAF—Bladder Cancer—MMP1—systemic scleroderma	0.000856	0.0154	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.000821	0.0148	CbGpPWpGaD
Vemurafenib—RAF1—Endothelins—COL1A2—systemic scleroderma	0.000738	0.0133	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000726	0.0131	CbGpPWpGaD
Vemurafenib—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	0.000719	0.0129	CbGpPWpGaD
Vemurafenib—BRAF—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.000712	0.0128	CbGpPWpGaD
Vemurafenib—RAF1—BCR signaling pathway—CSK—systemic scleroderma	0.000678	0.0122	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000673	0.0121	CbGpPWpGaD
Vemurafenib—RAF1—Endothelin Pathways—EDN1—systemic scleroderma	0.00067	0.0121	CbGpPWpGaD
Vemurafenib—BRAF—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.000669	0.012	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.000645	0.0116	CbGpPWpGaD
Vemurafenib—BRAF—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000634	0.0114	CbGpPWpGaD
Vemurafenib—BRAF—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000595	0.0107	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.000568	0.0102	CbGpPWpGaD
Vemurafenib—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.00056	0.0101	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.00056	0.0101	CbGpPWpGaD
Vemurafenib—Oedema peripheral—Lisinopril—systemic scleroderma	0.000522	0.00239	CcSEcCtD
Vemurafenib—Fatigue—Mometasone—systemic scleroderma	0.000521	0.00238	CcSEcCtD
Vemurafenib—Alopecia—Mycophenolic acid—systemic scleroderma	0.00052	0.00238	CcSEcCtD
Vemurafenib—Back pain—Leflunomide—systemic scleroderma	0.000519	0.00237	CcSEcCtD
Vemurafenib—BRAF—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000518	0.00933	CbGpPWpGaD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000517	0.00932	CbGpPWpGaD
Vemurafenib—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000517	0.00236	CcSEcCtD
Vemurafenib—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000517	0.00236	CcSEcCtD
Vemurafenib—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000516	0.00236	CcSEcCtD
Vemurafenib—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000512	0.00234	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.000507	0.00232	CcSEcCtD
Vemurafenib—RAF1—TCR Signaling Pathway—CD247—systemic scleroderma	0.000504	0.00907	CbGpPWpGaD
Vemurafenib—Asthenia—Pentoxifylline—systemic scleroderma	0.000503	0.0023	CcSEcCtD
Vemurafenib—Erythema multiforme—Lisinopril—systemic scleroderma	0.000501	0.00229	CcSEcCtD
Vemurafenib—Hypotension—Captopril—systemic scleroderma	0.000496	0.00227	CcSEcCtD
Vemurafenib—Pruritus—Pentoxifylline—systemic scleroderma	0.000496	0.00227	CcSEcCtD
Vemurafenib—Back pain—Mycophenolic acid—systemic scleroderma	0.000495	0.00226	CcSEcCtD
Vemurafenib—RAF1—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.000492	0.00887	CbGpPWpGaD
Vemurafenib—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000484	0.00221	CcSEcCtD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000484	0.00871	CbGpPWpGaD
Vemurafenib—Arthralgia—Azathioprine—systemic scleroderma	0.000484	0.00221	CcSEcCtD
Vemurafenib—Myalgia—Azathioprine—systemic scleroderma	0.000484	0.00221	CcSEcCtD
Vemurafenib—Angiopathy—Lisinopril—systemic scleroderma	0.00048	0.0022	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00048	0.0022	CcSEcCtD
Vemurafenib—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00048	0.00219	CcSEcCtD
Vemurafenib—Body temperature increased—Mometasone—systemic scleroderma	0.000478	0.00219	CcSEcCtD
Vemurafenib—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000478	0.0086	CbGpPWpGaD
Vemurafenib—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000477	0.00218	CcSEcCtD
Vemurafenib—Chills—Lisinopril—systemic scleroderma	0.000475	0.00217	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—systemic scleroderma	0.000473	0.00216	CcSEcCtD
Vemurafenib—Cough—Leflunomide—systemic scleroderma	0.000468	0.00214	CcSEcCtD
Vemurafenib—Alopecia—Lisinopril—systemic scleroderma	0.000468	0.00214	CcSEcCtD
Vemurafenib—BRAF—Focal Adhesion—RHOB—systemic scleroderma	0.000467	0.00842	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000467	0.00841	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000466	0.00839	CbGpPWpGaD
Vemurafenib—Dizziness—Pentoxifylline—systemic scleroderma	0.000464	0.00212	CcSEcCtD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000463	0.00834	CbGpPWpGaD
Vemurafenib—RAF1—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.000463	0.00834	CbGpPWpGaD
Vemurafenib—Decreased appetite—Captopril—systemic scleroderma	0.000462	0.00211	CcSEcCtD
Vemurafenib—Erythema—Lisinopril—systemic scleroderma	0.000461	0.00211	CcSEcCtD
Vemurafenib—Malnutrition—Lisinopril—systemic scleroderma	0.000461	0.00211	CcSEcCtD
Vemurafenib—Infection—Azathioprine—systemic scleroderma	0.000461	0.00211	CcSEcCtD
Vemurafenib—Fatigue—Captopril—systemic scleroderma	0.000458	0.00209	CcSEcCtD
Vemurafenib—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000457	0.00209	CcSEcCtD
Vemurafenib—Arthralgia—Leflunomide—systemic scleroderma	0.000457	0.00209	CcSEcCtD
Vemurafenib—Myalgia—Leflunomide—systemic scleroderma	0.000457	0.00209	CcSEcCtD
Vemurafenib—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000456	0.00209	CcSEcCtD
Vemurafenib—Constipation—Captopril—systemic scleroderma	0.000454	0.00208	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000454	0.00207	CcSEcCtD
Vemurafenib—Dysgeusia—Lisinopril—systemic scleroderma	0.000451	0.00206	CcSEcCtD
Vemurafenib—Skin disorder—Azathioprine—systemic scleroderma	0.00045	0.00206	CcSEcCtD
Vemurafenib—Cough—Mycophenolic acid—systemic scleroderma	0.000447	0.00204	CcSEcCtD
Vemurafenib—Back pain—Lisinopril—systemic scleroderma	0.000446	0.00204	CcSEcCtD
Vemurafenib—Vomiting—Pentoxifylline—systemic scleroderma	0.000446	0.00204	CcSEcCtD
Vemurafenib—Rash—Pentoxifylline—systemic scleroderma	0.000442	0.00202	CcSEcCtD
Vemurafenib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000442	0.00202	CcSEcCtD
Vemurafenib—BRAF—Focal Adhesion—COL1A2—systemic scleroderma	0.000441	0.00794	CbGpPWpGaD
Vemurafenib—Headache—Pentoxifylline—systemic scleroderma	0.000439	0.00201	CcSEcCtD
Vemurafenib—RAF1—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000439	0.0079	CbGpPWpGaD
Vemurafenib—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000438	0.002	CcSEcCtD
Vemurafenib—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000436	0.00199	CcSEcCtD
Vemurafenib—Myalgia—Mycophenolic acid—systemic scleroderma	0.000436	0.00199	CcSEcCtD
Vemurafenib—Infection—Leflunomide—systemic scleroderma	0.000435	0.00199	CcSEcCtD
Vemurafenib—Asthenia—Mometasone—systemic scleroderma	0.000434	0.00198	CcSEcCtD
Vemurafenib—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000434	0.00198	CcSEcCtD
Vemurafenib—Hypotension—Azathioprine—systemic scleroderma	0.000433	0.00198	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000433	0.00198	CcSEcCtD
Vemurafenib—Photosensitivity—Methotrexate—systemic scleroderma	0.000433	0.00198	CcSEcCtD
Vemurafenib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000431	0.00197	CcSEcCtD
Vemurafenib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000429	0.00196	CcSEcCtD
Vemurafenib—Pruritus—Mometasone—systemic scleroderma	0.000428	0.00196	CcSEcCtD
Vemurafenib—Skin disorder—Leflunomide—systemic scleroderma	0.000425	0.00194	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000422	0.00193	CcSEcCtD
Vemurafenib—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000421	0.00193	CcSEcCtD
Vemurafenib—Body temperature increased—Captopril—systemic scleroderma	0.00042	0.00192	CcSEcCtD
Vemurafenib—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.000419	0.00755	CbGpPWpGaD
Vemurafenib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000418	0.00191	CcSEcCtD
Vemurafenib—RAF1—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.000418	0.00753	CbGpPWpGaD
Vemurafenib—Dry skin—Prednisone—systemic scleroderma	0.000417	0.00191	CcSEcCtD
Vemurafenib—Nausea—Pentoxifylline—systemic scleroderma	0.000416	0.0019	CcSEcCtD
Vemurafenib—Chills—Mycophenolate mofetil—systemic scleroderma	0.000416	0.0019	CcSEcCtD
Vemurafenib—Infection—Mycophenolic acid—systemic scleroderma	0.000415	0.0019	CcSEcCtD
Vemurafenib—Diarrhoea—Mometasone—systemic scleroderma	0.000414	0.00189	CcSEcCtD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000412	0.00742	CbGpPWpGaD
Vemurafenib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00041	0.00187	CcSEcCtD
Vemurafenib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00041	0.00187	CcSEcCtD
Vemurafenib—Hypotension—Leflunomide—systemic scleroderma	0.000409	0.00187	CcSEcCtD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.000408	0.00735	CbGpPWpGaD
Vemurafenib—RAF1—Endothelin Pathways—NOS3—systemic scleroderma	0.000408	0.00735	CbGpPWpGaD
Vemurafenib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000406	0.00186	CcSEcCtD
Vemurafenib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00185	CcSEcCtD
Vemurafenib—Cough—Lisinopril—systemic scleroderma	0.000402	0.00184	CcSEcCtD
Vemurafenib—BRAF—Focal Adhesion—ITGAM—systemic scleroderma	0.0004	0.00721	CbGpPWpGaD
Vemurafenib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.0004	0.00183	CcSEcCtD
Vemurafenib—RAF1—Endothelins—EDN1—systemic scleroderma	0.000399	0.00719	CbGpPWpGaD
Vemurafenib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000399	0.00182	CcSEcCtD
Vemurafenib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000396	0.00181	CcSEcCtD
Vemurafenib—Arthralgia—Lisinopril—systemic scleroderma	0.000392	0.00179	CcSEcCtD
Vemurafenib—Myalgia—Lisinopril—systemic scleroderma	0.000392	0.00179	CcSEcCtD
Vemurafenib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000391	0.00179	CcSEcCtD
Vemurafenib—Hypotension—Mycophenolic acid—systemic scleroderma	0.00039	0.00178	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00039	0.00178	CcSEcCtD
Vemurafenib—Vomiting—Mometasone—systemic scleroderma	0.000385	0.00176	CcSEcCtD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000381	0.00687	CbGpPWpGaD
Vemurafenib—Rash—Mometasone—systemic scleroderma	0.000381	0.00174	CcSEcCtD
Vemurafenib—Asthenia—Captopril—systemic scleroderma	0.000381	0.00174	CcSEcCtD
Vemurafenib—Dermatitis—Mometasone—systemic scleroderma	0.000381	0.00174	CcSEcCtD
Vemurafenib—Decreased appetite—Leflunomide—systemic scleroderma	0.000381	0.00174	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000381	0.00174	CcSEcCtD
Vemurafenib—Headache—Mometasone—systemic scleroderma	0.000379	0.00173	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000378	0.00173	CcSEcCtD
Vemurafenib—RAF1—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000378	0.0068	CbGpPWpGaD
Vemurafenib—Fatigue—Leflunomide—systemic scleroderma	0.000377	0.00173	CcSEcCtD
Vemurafenib—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000376	0.00172	CcSEcCtD
Vemurafenib—Pruritus—Captopril—systemic scleroderma	0.000376	0.00172	CcSEcCtD
Vemurafenib—Constipation—Leflunomide—systemic scleroderma	0.000374	0.00171	CcSEcCtD
Vemurafenib—Infection—Lisinopril—systemic scleroderma	0.000374	0.00171	CcSEcCtD
Vemurafenib—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000373	0.00671	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—BLK—systemic scleroderma	0.00037	0.00667	CbGpPWpGaD
Vemurafenib—Body temperature increased—Azathioprine—systemic scleroderma	0.000367	0.00168	CcSEcCtD
Vemurafenib—Skin disorder—Lisinopril—systemic scleroderma	0.000365	0.00167	CcSEcCtD
Vemurafenib—Diarrhoea—Captopril—systemic scleroderma	0.000363	0.00166	CcSEcCtD
Vemurafenib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000363	0.00166	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000361	0.00165	CcSEcCtD
Vemurafenib—Fatigue—Mycophenolic acid—systemic scleroderma	0.00036	0.00165	CcSEcCtD
Vemurafenib—Nausea—Mometasone—systemic scleroderma	0.000359	0.00164	CcSEcCtD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000358	0.00645	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000358	0.00645	CbGpPWpGaD
Vemurafenib—Constipation—Mycophenolic acid—systemic scleroderma	0.000357	0.00163	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—systemic scleroderma	0.000355	0.00163	CcSEcCtD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000355	0.00639	CbGpPWpGaD
Vemurafenib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000352	0.00161	CcSEcCtD
Vemurafenib—Hypotension—Lisinopril—systemic scleroderma	0.000352	0.00161	CcSEcCtD
Vemurafenib—Dizziness—Captopril—systemic scleroderma	0.000351	0.00161	CcSEcCtD
Vemurafenib—Body temperature increased—Leflunomide—systemic scleroderma	0.000346	0.00158	CcSEcCtD
Vemurafenib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000344	0.00157	CcSEcCtD
Vemurafenib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000344	0.00157	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000343	0.00157	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000343	0.00157	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000342	0.00156	CcSEcCtD
Vemurafenib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000342	0.00156	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000341	0.00156	CcSEcCtD
Vemurafenib—Vomiting—Captopril—systemic scleroderma	0.000338	0.00154	CcSEcCtD
Vemurafenib—RAF1—Endothelins—MMP1—systemic scleroderma	0.000336	0.00605	CbGpPWpGaD
Vemurafenib—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000336	0.00605	CbGpPWpGaD
Vemurafenib—Rash—Captopril—systemic scleroderma	0.000335	0.00153	CcSEcCtD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000335	0.00603	CbGpPWpGaD
Vemurafenib—Dermatitis—Captopril—systemic scleroderma	0.000335	0.00153	CcSEcCtD
Vemurafenib—Headache—Captopril—systemic scleroderma	0.000333	0.00152	CcSEcCtD
Vemurafenib—BRAF—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000331	0.00596	CbGpPWpGaD
Vemurafenib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00033	0.00151	CcSEcCtD
Vemurafenib—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.00033	0.00595	CbGpPWpGaD
Vemurafenib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00033	0.00151	CcSEcCtD
Vemurafenib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000327	0.0015	CcSEcCtD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000327	0.0059	CbGpPWpGaD
Vemurafenib—Decreased appetite—Lisinopril—systemic scleroderma	0.000327	0.0015	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—systemic scleroderma	0.000325	0.00149	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000325	0.00149	CcSEcCtD
Vemurafenib—Fatigue—Lisinopril—systemic scleroderma	0.000324	0.00148	CcSEcCtD
Vemurafenib—RAF1—Focal Adhesion—RHOB—systemic scleroderma	0.000323	0.00583	CbGpPWpGaD
Vemurafenib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000323	0.00148	CcSEcCtD
Vemurafenib—Hypersensitivity—Leflunomide—systemic scleroderma	0.000323	0.00148	CcSEcCtD
Vemurafenib—Constipation—Lisinopril—systemic scleroderma	0.000322	0.00147	CcSEcCtD
Vemurafenib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00032	0.00146	CcSEcCtD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000317	0.00571	CbGpPWpGaD
Vemurafenib—Diarrhoea—Azathioprine—systemic scleroderma	0.000317	0.00145	CcSEcCtD
Vemurafenib—Nausea—Captopril—systemic scleroderma	0.000316	0.00144	CcSEcCtD
Vemurafenib—Asthenia—Leflunomide—systemic scleroderma	0.000314	0.00144	CcSEcCtD
Vemurafenib—Pruritus—Leflunomide—systemic scleroderma	0.00031	0.00142	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000309	0.00141	CcSEcCtD
Vemurafenib—RAF1—Signaling by EGFR—CSK—systemic scleroderma	0.000309	0.00557	CbGpPWpGaD
Vemurafenib—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000308	0.00141	CcSEcCtD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000307	0.00553	CbGpPWpGaD
Vemurafenib—Dizziness—Azathioprine—systemic scleroderma	0.000307	0.0014	CcSEcCtD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000306	0.00552	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—COL1A2—systemic scleroderma	0.000305	0.00549	CbGpPWpGaD
Vemurafenib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.0003	0.00137	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.0003	0.00137	CcSEcCtD
Vemurafenib—Asthenia—Mycophenolic acid—systemic scleroderma	0.0003	0.00137	CcSEcCtD
Vemurafenib—Diarrhoea—Leflunomide—systemic scleroderma	0.0003	0.00137	CcSEcCtD
Vemurafenib—RAF1—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000298	0.00538	CbGpPWpGaD
Vemurafenib—Body temperature increased—Lisinopril—systemic scleroderma	0.000297	0.00136	CcSEcCtD
Vemurafenib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000296	0.00135	CcSEcCtD
Vemurafenib—Vomiting—Azathioprine—systemic scleroderma	0.000295	0.00135	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—systemic scleroderma	0.000294	0.00134	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—systemic scleroderma	0.000293	0.00134	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—systemic scleroderma	0.000293	0.00134	CcSEcCtD
Vemurafenib—Rash—Azathioprine—systemic scleroderma	0.000292	0.00134	CcSEcCtD
Vemurafenib—Dermatitis—Azathioprine—systemic scleroderma	0.000292	0.00134	CcSEcCtD
Vemurafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.000291	0.00525	CbGpPWpGaD
Vemurafenib—Headache—Azathioprine—systemic scleroderma	0.00029	0.00133	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00029	0.00133	CcSEcCtD
Vemurafenib—Dizziness—Leflunomide—systemic scleroderma	0.00029	0.00132	CcSEcCtD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000287	0.00516	CbGpPWpGaD
Vemurafenib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000287	0.00131	CcSEcCtD
Vemurafenib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000286	0.00131	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—systemic scleroderma	0.000285	0.0013	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000285	0.0013	CcSEcCtD
Vemurafenib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000282	0.00129	CcSEcCtD
Vemurafenib—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.00028	0.00504	CbGpPWpGaD
Vemurafenib—Vomiting—Leflunomide—systemic scleroderma	0.000278	0.00127	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—systemic scleroderma	0.000278	0.00127	CcSEcCtD
Vemurafenib—Hypersensitivity—Lisinopril—systemic scleroderma	0.000277	0.00127	CcSEcCtD
Vemurafenib—RAF1—Focal Adhesion—ITGAM—systemic scleroderma	0.000277	0.00499	CbGpPWpGaD
Vemurafenib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000276	0.00126	CcSEcCtD
Vemurafenib—Rash—Leflunomide—systemic scleroderma	0.000276	0.00126	CcSEcCtD
Vemurafenib—Dermatitis—Leflunomide—systemic scleroderma	0.000276	0.00126	CcSEcCtD
Vemurafenib—Nausea—Azathioprine—systemic scleroderma	0.000275	0.00126	CcSEcCtD
Vemurafenib—Headache—Leflunomide—systemic scleroderma	0.000274	0.00125	CcSEcCtD
Vemurafenib—Erythema—Prednisone—systemic scleroderma	0.000274	0.00125	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—systemic scleroderma	0.000274	0.00125	CcSEcCtD
Vemurafenib—RAF1—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.00027	0.00486	CbGpPWpGaD
Vemurafenib—Asthenia—Lisinopril—systemic scleroderma	0.00027	0.00123	CcSEcCtD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000266	0.0048	CbGpPWpGaD
Vemurafenib—Pruritus—Lisinopril—systemic scleroderma	0.000266	0.00122	CcSEcCtD
Vemurafenib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000266	0.00121	CcSEcCtD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000264	0.00475	CbGpPWpGaD
Vemurafenib—Rash—Mycophenolic acid—systemic scleroderma	0.000263	0.0012	CcSEcCtD
Vemurafenib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000263	0.0012	CcSEcCtD
Vemurafenib—BRAF—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000262	0.00472	CbGpPWpGaD
Vemurafenib—Headache—Mycophenolic acid—systemic scleroderma	0.000262	0.0012	CcSEcCtD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000261	0.0047	CbGpPWpGaD
Vemurafenib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000261	0.00119	CcSEcCtD
Vemurafenib—Nausea—Leflunomide—systemic scleroderma	0.00026	0.00119	CcSEcCtD
Vemurafenib—RAF1—SHP2 signaling—NOS3—systemic scleroderma	0.00026	0.00468	CbGpPWpGaD
Vemurafenib—BRAF—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.00026	0.00468	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL1A—systemic scleroderma	0.000258	0.00465	CbGpPWpGaD
Vemurafenib—Diarrhoea—Lisinopril—systemic scleroderma	0.000257	0.00118	CcSEcCtD
Vemurafenib—RAF1—Focal Adhesion—BLK—systemic scleroderma	0.000256	0.00462	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—MMP2—systemic scleroderma	0.00025	0.00451	CbGpPWpGaD
Vemurafenib—Dizziness—Lisinopril—systemic scleroderma	0.000249	0.00114	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—systemic scleroderma	0.000249	0.00114	CcSEcCtD
Vemurafenib—Nausea—Mycophenolic acid—systemic scleroderma	0.000248	0.00113	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—systemic scleroderma	0.000246	0.00112	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000244	0.00112	CcSEcCtD
Vemurafenib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00111	CcSEcCtD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000241	0.00434	CbGpPWpGaD
Vemurafenib—Vomiting—Lisinopril—systemic scleroderma	0.000239	0.00109	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—systemic scleroderma	0.000238	0.00109	CcSEcCtD
Vemurafenib—Rash—Lisinopril—systemic scleroderma	0.000237	0.00108	CcSEcCtD
Vemurafenib—Dermatitis—Lisinopril—systemic scleroderma	0.000237	0.00108	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000237	0.00108	CcSEcCtD
Vemurafenib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000236	0.00108	CcSEcCtD
Vemurafenib—Chills—Methotrexate—systemic scleroderma	0.000236	0.00108	CcSEcCtD
Vemurafenib—Headache—Lisinopril—systemic scleroderma	0.000236	0.00108	CcSEcCtD
Vemurafenib—RAF1—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000234	0.00422	CbGpPWpGaD
Vemurafenib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000233	0.00107	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—systemic scleroderma	0.000233	0.00107	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—systemic scleroderma	0.000233	0.00107	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—systemic scleroderma	0.000232	0.00106	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000231	0.00106	CcSEcCtD
Vemurafenib—RAF1—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000229	0.00412	CbGpPWpGaD
Vemurafenib—Malnutrition—Methotrexate—systemic scleroderma	0.000229	0.00105	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—systemic scleroderma	0.000229	0.00105	CcSEcCtD
Vemurafenib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000226	0.00103	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—systemic scleroderma	0.000224	0.00102	CcSEcCtD
Vemurafenib—Nausea—Lisinopril—systemic scleroderma	0.000223	0.00102	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—systemic scleroderma	0.000223	0.00102	CcSEcCtD
Vemurafenib—Infection—Prednisone—systemic scleroderma	0.000222	0.00102	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—systemic scleroderma	0.000221	0.00101	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—systemic scleroderma	0.000219	0.001	CcSEcCtD
Vemurafenib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000997	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—systemic scleroderma	0.000217	0.000993	CcSEcCtD
Vemurafenib—RAF1—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000214	0.00386	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000213	0.00383	CbGpPWpGaD
Vemurafenib—RAF1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000212	0.00381	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—RHOB—systemic scleroderma	0.000211	0.0038	CbGpPWpGaD
Vemurafenib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00021	0.000958	CcSEcCtD
Vemurafenib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00095	CcSEcCtD
Vemurafenib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00095	CcSEcCtD
Vemurafenib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000206	0.000944	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000204	0.000931	CcSEcCtD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000203	0.00366	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000202	0.00363	CbGpPWpGaD
Vemurafenib—Cough—Methotrexate—systemic scleroderma	0.0002	0.000913	CcSEcCtD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000199	0.00358	CbGpPWpGaD
Vemurafenib—RAF1—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000197	0.00354	CbGpPWpGaD
Vemurafenib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000196	0.000895	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—systemic scleroderma	0.000195	0.000891	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—systemic scleroderma	0.000195	0.000891	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—systemic scleroderma	0.000194	0.000888	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000193	0.000885	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—systemic scleroderma	0.000193	0.000881	CcSEcCtD
Vemurafenib—Constipation—Prednisone—systemic scleroderma	0.000191	0.000874	CcSEcCtD
Vemurafenib—RAF1—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000188	0.00339	CbGpPWpGaD
Vemurafenib—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000187	0.000854	CcSEcCtD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000186	0.00335	CbGpPWpGaD
Vemurafenib—Infection—Methotrexate—systemic scleroderma	0.000186	0.000848	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000183	0.000837	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—systemic scleroderma	0.000181	0.000829	CcSEcCtD
Vemurafenib—RAF1—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000181	0.00326	CbGpPWpGaD
Vemurafenib—RAF1—Leptin signaling pathway—IL1B—systemic scleroderma	0.00018	0.00324	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.00018	0.00324	CbGpPWpGaD
Vemurafenib—RAF1—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000179	0.00323	CbGpPWpGaD
Vemurafenib—Body temperature increased—Prednisone—systemic scleroderma	0.000177	0.000808	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—systemic scleroderma	0.000174	0.000798	CcSEcCtD
Vemurafenib—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000174	0.00313	CbGpPWpGaD
Vemurafenib—BRAF—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000172	0.00309	CbGpPWpGaD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00017	0.000778	CcSEcCtD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000165	0.00298	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000165	0.00298	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Prednisone—systemic scleroderma	0.000165	0.000753	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—systemic scleroderma	0.000162	0.000742	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000161	0.000737	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—systemic scleroderma	0.000161	0.000736	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—systemic scleroderma	0.00016	0.000733	CcSEcCtD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000159	0.00287	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SELP—systemic scleroderma	0.000158	0.00285	CbGpPWpGaD
Vemurafenib—Pruritus—Prednisone—systemic scleroderma	0.000158	0.000723	CcSEcCtD
Vemurafenib—RAF1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000156	0.0028	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000155	0.00278	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000154	0.00278	CbGpPWpGaD
Vemurafenib—Diarrhoea—Prednisone—systemic scleroderma	0.000153	0.000699	CcSEcCtD
Vemurafenib—RAF1—Developmental Biology—RHOB—systemic scleroderma	0.000151	0.00271	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—NOS3—systemic scleroderma	0.00015	0.00271	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.00015	0.00269	CbGpPWpGaD
Vemurafenib—Dizziness—Prednisone—systemic scleroderma	0.000148	0.000676	CcSEcCtD
Vemurafenib—RAF1—Hemostasis—RHOB—systemic scleroderma	0.000148	0.00266	CbGpPWpGaD
Vemurafenib—Body temperature increased—Methotrexate—systemic scleroderma	0.000148	0.000675	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—systemic scleroderma	0.000142	0.00065	CcSEcCtD
Vemurafenib—ALB—Folate Metabolism—CCL2—systemic scleroderma	0.000142	0.00255	CbGpPWpGaD
Vemurafenib—Rash—Prednisone—systemic scleroderma	0.000141	0.000644	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—systemic scleroderma	0.000141	0.000644	CcSEcCtD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.00014	0.00253	CbGpPWpGaD
Vemurafenib—Headache—Prednisone—systemic scleroderma	0.00014	0.00064	CcSEcCtD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000138	0.00248	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Methotrexate—systemic scleroderma	0.000138	0.000629	CcSEcCtD
Vemurafenib—BRAF—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000137	0.00246	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—CSK—systemic scleroderma	0.000135	0.00242	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL1B—systemic scleroderma	0.000135	0.00242	CbGpPWpGaD
Vemurafenib—Asthenia—Methotrexate—systemic scleroderma	0.000134	0.000613	CcSEcCtD
Vemurafenib—BRAF—Disease—SMAD7—systemic scleroderma	0.000134	0.00241	CbGpPWpGaD
Vemurafenib—Nausea—Prednisone—systemic scleroderma	0.000133	0.000607	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—systemic scleroderma	0.000132	0.000604	CcSEcCtD
Vemurafenib—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000132	0.00238	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000128	0.0023	CbGpPWpGaD
Vemurafenib—Diarrhoea—Methotrexate—systemic scleroderma	0.000128	0.000584	CcSEcCtD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000127	0.00228	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ITGAM—systemic scleroderma	0.000127	0.00228	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000126	0.00226	CbGpPWpGaD
Vemurafenib—Dizziness—Methotrexate—systemic scleroderma	0.000123	0.000565	CcSEcCtD
Vemurafenib—BRAF—Disease—TGFBI—systemic scleroderma	0.000122	0.0022	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000121	0.00218	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.00012	0.00217	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000119	0.00214	CbGpPWpGaD
Vemurafenib—Vomiting—Methotrexate—systemic scleroderma	0.000119	0.000543	CcSEcCtD
Vemurafenib—Rash—Methotrexate—systemic scleroderma	0.000118	0.000538	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—systemic scleroderma	0.000118	0.000538	CcSEcCtD
Vemurafenib—Headache—Methotrexate—systemic scleroderma	0.000117	0.000535	CcSEcCtD
Vemurafenib—RAF1—Adaptive Immune System—CSK—systemic scleroderma	0.000116	0.0021	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000114	0.00206	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ITGAM—systemic scleroderma	0.000114	0.00205	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD247—systemic scleroderma	0.000114	0.00205	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000112	0.00203	CbGpPWpGaD
Vemurafenib—Nausea—Methotrexate—systemic scleroderma	0.000111	0.000507	CcSEcCtD
Vemurafenib—RAF1—Adaptive Immune System—CD247—systemic scleroderma	0.000109	0.00197	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL1B—systemic scleroderma	0.000107	0.00193	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000107	0.00193	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000107	0.00192	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000106	0.00191	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000102	0.00185	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—BLK—systemic scleroderma	0.000101	0.00182	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.0001	0.00181	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HSPG2—systemic scleroderma	9.75e-05	0.00176	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.53e-05	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—IL1B—systemic scleroderma	9.45e-05	0.0017	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CSK—systemic scleroderma	9.42e-05	0.0017	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMAD7—systemic scleroderma	9.36e-05	0.00169	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SMAD7—systemic scleroderma	9.25e-05	0.00167	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SMAD7—systemic scleroderma	9.16e-05	0.00165	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	8.9e-05	0.0016	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD247—systemic scleroderma	8.85e-05	0.00159	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	8.53e-05	0.00154	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SELP—systemic scleroderma	8.52e-05	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—RHOB—systemic scleroderma	8.48e-05	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFBI—systemic scleroderma	8.46e-05	0.00152	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFBI—systemic scleroderma	8.38e-05	0.00151	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CTLA4—systemic scleroderma	8.29e-05	0.00149	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RHOB—systemic scleroderma	7.95e-05	0.00143	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	7.79e-05	0.0014	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	7.34e-05	0.00132	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—CSK—systemic scleroderma	7.24e-05	0.0013	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RHOB—systemic scleroderma	7.24e-05	0.0013	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—TGFB1—systemic scleroderma	7.15e-05	0.00129	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CSK—systemic scleroderma	7.06e-05	0.00127	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP2—systemic scleroderma	7.01e-05	0.00126	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IRF5—systemic scleroderma	6.94e-05	0.00125	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HSPG2—systemic scleroderma	6.83e-05	0.00123	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.83e-05	0.00123	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	6.83e-05	0.00123	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	6.81e-05	0.00123	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ITGAM—systemic scleroderma	6.81e-05	0.00123	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HSPG2—systemic scleroderma	6.74e-05	0.00121	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HSPG2—systemic scleroderma	6.69e-05	0.0012	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IRF8—systemic scleroderma	6.63e-05	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ITGAM—systemic scleroderma	6.63e-05	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD247—systemic scleroderma	6.63e-05	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.63e-05	0.00119	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CSK—systemic scleroderma	6.59e-05	0.00119	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CSK—systemic scleroderma	6.51e-05	0.00117	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMAD7—systemic scleroderma	6.47e-05	0.00117	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CSK—systemic scleroderma	6.46e-05	0.00116	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD40LG—systemic scleroderma	6.45e-05	0.00116	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—MMP1—systemic scleroderma	6.34e-05	0.00114	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	6.28e-05	0.00113	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TNFAIP3—systemic scleroderma	6.21e-05	0.00112	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BLK—systemic scleroderma	6.14e-05	0.00111	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD247—systemic scleroderma	6.12e-05	0.0011	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD247—systemic scleroderma	6.07e-05	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	5.9e-05	0.00106	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HSPG2—systemic scleroderma	5.6e-05	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—systemic scleroderma	5.27e-05	0.000949	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.17e-05	0.000932	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTLA4—systemic scleroderma	5.03e-05	0.000906	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RHOB—systemic scleroderma	5.01e-05	0.000902	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—systemic scleroderma	5e-05	0.000901	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HSPG2—systemic scleroderma	4.93e-05	0.000887	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.77e-05	0.00086	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HSPG2—systemic scleroderma	4.72e-05	0.000851	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS3—systemic scleroderma	4.6e-05	0.000828	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CSK—systemic scleroderma	4.56e-05	0.000822	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EDN1—systemic scleroderma	4.33e-05	0.00078	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CTGF—systemic scleroderma	4.24e-05	0.000764	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQB1—systemic scleroderma	4.14e-05	0.000746	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1A—systemic scleroderma	3.93e-05	0.000708	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—systemic scleroderma	3.91e-05	0.000704	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—systemic scleroderma	3.76e-05	0.000677	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CTGF—systemic scleroderma	3.73e-05	0.000673	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EDN1—systemic scleroderma	3.7e-05	0.000666	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.62e-05	0.000652	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MMP1—systemic scleroderma	3.41e-05	0.000615	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS3—systemic scleroderma	3.22e-05	0.000579	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.17e-05	0.000572	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—systemic scleroderma	3.1e-05	0.000558	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HSPG2—systemic scleroderma	3.04e-05	0.000548	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—systemic scleroderma	3.04e-05	0.000547	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—systemic scleroderma	2.96e-05	0.000533	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EDN1—systemic scleroderma	2.56e-05	0.000461	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—systemic scleroderma	2.53e-05	0.000455	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	2.51e-05	0.000452	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—systemic scleroderma	2.47e-05	0.000446	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CTGF—systemic scleroderma	2.3e-05	0.000415	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—systemic scleroderma	2.25e-05	0.000406	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—systemic scleroderma	2.22e-05	0.000401	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—systemic scleroderma	2.21e-05	0.000397	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—systemic scleroderma	2.13e-05	0.000383	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	2.13e-05	0.000383	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—systemic scleroderma	2.05e-05	0.000369	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.9e-05	0.000343	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—systemic scleroderma	1.85e-05	0.000333	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—systemic scleroderma	1.81e-05	0.000325	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—systemic scleroderma	1.75e-05	0.000315	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.64e-05	0.000296	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—systemic scleroderma	1.64e-05	0.000295	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—systemic scleroderma	1.63e-05	0.000293	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTGF—systemic scleroderma	1.61e-05	0.00029	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—systemic scleroderma	1.56e-05	0.000281	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—systemic scleroderma	1.49e-05	0.000268	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—systemic scleroderma	1.47e-05	0.000265	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—systemic scleroderma	1.46e-05	0.000263	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—systemic scleroderma	1.25e-05	0.000225	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.24e-05	0.000224	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—systemic scleroderma	1.03e-05	0.000186	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—systemic scleroderma	1e-05	0.000181	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—systemic scleroderma	8.28e-06	0.000149	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—systemic scleroderma	7.01e-06	0.000126	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—systemic scleroderma	5.41e-06	9.75e-05	CbGpPWpGaD
